Bayer 3Q Net Sales EU10.19B; Est. EU9.97B

Bayer, a German pharmaceuticals and chemicals giant, reported strong financial results, surpassing estimates in several areas. The company achieved higher-than-expected earnings before interest, tax, depreciation, and amortization (EBITDA) and net sales for the third quarter. As a result, Bayer raised its full-year forecast. The company is shifting its focus more towards healthcare, moving away from chemicals. Notably, the blood thinner drug Xarelto saw significant sales growth, and the Merck acquisition contributed positively to sales and EBITDA. Overall, Bayer's performance led to an upgrade in full-year expectations.

What changes is Bayer making in its business focus according to the report?

What product is mentioned as a key contributor to Bayer's performance, and what type of drug is it?